Mechanism of Action
SSTR1-5 Receptor Signaling
All five somatostatin receptors are Gi-coupled GPCRs that inhibit adenylyl cyclase, reducing cAMP. They also activate inwardly rectifying K+ channels (hyperpolarizing cells) and inhibit voltage-gated Ca2+ channels, suppressing secretion across multiple cell types. SSTR2 and SSTR5 are primary targets on pituitary somatotrophs and pancreatic islets. Octreotide has highest affinity for SSTR2/5; pasireotide covers all five receptors.
Broad Inhibitory Actions
Somatostatin inhibits GH and TSH (pituitary), insulin and glucagon (pancreas), gastrin and secretin (GI), intestinal motility, and splanchnic blood flow. It also inhibits tumor cell proliferation via SSTR2-mediated antiproliferative signaling, making analogs useful for neuroendocrine tumor treatment beyond symptom control.
Research Summary
Acromegaly
FDA ApprovedOctreotide (Sandostatin) and lanreotide (Somatuline) are first-line medical therapy for acromegaly. Monthly LAR formulations normalize IGF-1 in 50-70% of patients. Pasireotide (Signifor LAR) provides additional benefit in octreotide-resistant cases by targeting all five SSTRs.
Neuroendocrine Tumors
FDA ApprovedSomatostatin analogs are standard of care for functional NETs. Lanreotide (Clarinet trial) and octreotide LAR (PROMID trial) demonstrate progression-free survival benefit in well-differentiated NETs. Radiolabeled somatostatin analogs (Lu-177 DOTATATE) are approved for SSTR-expressing NETs.
Cushing's Disease
FDA ApprovedPasireotide (Signifor) is FDA-approved for Cushing's disease via SSTR5 agonism on corticotroph adenomas. It reduces urinary free cortisol by ~50% in ~25% of patients.
Calculate your Somatostatin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Acromegaly (octreotide LAR) | 20-30 mg IM monthly | Every 4 weeks | Intramuscular depot |
| Carcinoid syndrome (octreotide SC) | 100-600 ug/day divided | 3x daily or pump | Subcutaneous |
| Cushing's disease (pasireotide SC) | 0.6-0.9 mg SC twice daily | Twice daily | Subcutaneous |
Native somatostatin (1-3 min half-life) is not used clinically. All therapeutic applications use stable analogs.
Interactions
Safety Profile
Common side effects: GI symptoms (diarrhea, nausea, abdominal cramps) typically improving with continued use; gallstone formation (~20-30% with long-term use); glucose dysregulation (hyperglycemia especially with pasireotide). Bradycardia possible. No WADA listing.
References
- [1]Brazeau P, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179(4068):77-79.
- [2]Rinke A, et al. Placebo-controlled, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors. J Clin Oncol. 2009;27(28):4656-4663.
- [3]Colao A, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791-799.